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INTRODUCTION
Prevalence  of  Type  2  Diabetes  mellitus  is  rapidly  increasing  and  is 
already  an  epidemic  in  India.  Diabetes  mellitus  is  an  important  risk  factor 
associated with increased incidence of cardiovascular disease (CVD).
Prevalence  of  CVD  has  rapidly  increased  in  the  past  few  years.  The 
four  major  risk  factors  for  CVD  are  hypercholesterolemia,  hypertension, 
diabetes mellitus and cigarette smoking.
Insulin  resistance  state  is  associated  with  diabetes  mellitus  and 
metabolic  syndrome  (MS).  The  four  major  players  in  the  MS  are 
hyperinsulinemia,  hypertension,  hyperlipidemia,  and  hyperglycemia.  Each 
member  of  this  deadly  quartet  has  been  demonstrated  to  be  an  independent 
risk  factor  for  CHD  and  capable  of  working  together  in  a  synergistic 
manner  to  accelerate  both  non-diabetic  atherosclerosis  and  the 
atheroscleropathy associated with MS and T2DM.  
In  a  like  manner,  hyperuricemia,  hyperhomocysteinemia,  ROS,  and  highly 
sensitive  C-  reactive  protein  (hsCRP)  and  each  of  which  play  an  important  role  in 
expanding the original Syndrome X described by Reaven in the atherosclerotic process. 
The above quartet does not stand alone but interacts in a synergistic manner resulting in 
the progression of accelerated atherosclerosis and arterial vessel wall remodelling along 
with the original players.
The positive association between serum uric acid and cardiovascular diseases such 
as ischemic heart disease has been recognized since the 1950s and has been confirmed 
by  numerous  epidemiological  studies  since  then.  However,  whether  uric  acid  is  an 
independent risk factor for cardiovascular mortality is still disputed as several studies 
have  suggested  that  hyperuricemia  is  merely  associated with cardiovascular  diseases 
because  of  confounding  factors  such  as  obesity,  dyslipidemia,  hypertension,  use  of 
diuretics and insulin resistance.
Over  recent  years  there  has  been  renewed  debate  about  the  nature of  the 
association between raised serum uric  acid concentration and cardiovascular  disease. 
Several  studies  have  identified the  value,  in  populations,  of  serum  uric  acid 
concentration in  predicting  the  risk  of  cardiovascular  events,  such  as  myocardial 
infarction. This has directed the research towards the potential mechanisms by which 
uric acid might have direct or indirect effects on the cardiovascular system. It has been 
difficult to identify the specific role of elevated serum uric acid because of its association 
with  established  cardiovascular  risk  factors such  as  hypertension,  diabetes  mellitus, 
hyperlipidemia and obesity.
Here an attempt has been made to study the level of serum uric acid in 
type  2  diabetes  mellitus  and  the  correlation  between  elevated  serum  uric 
acid  levels  and  cardiovascular  risk  factors  like  obesity,  hypertension, 
smoking, dyslipidemia.
AIM OF THE STUDY
1. To identify the level of serum uric acid in Type 2 Diabetes mellitus.
2. To  identify  whether  any  association  exist  between  age,  sex,  anthropometric 
measurements  (BMI,  WHR),  hypertension,  dyslipidemia,  duration  of  diabetes, 
smoking  and coronary artery disease with serum uric acid level. 
REVIEW OF LITERATURE
Epidemiology of diabetes:
It  is  interesting  to  reflect  that  in  the  first  edition  of  the  IDF Diabetes  Atlas, 
released in 2000, the estimated global diabetes prevalence was 151 million. Now the 
estimated diabetes prevalence for 2010 has risen to 285 million, representing 6.4% of 
the world’s adult population, with a prediction that by 2030 the number of people with 
diabetes  will  have risen  to  438 million.  Far  from being a  disease  of  higher  income 
nations, diabetes is very much a disease associated with poverty, with the major burden 
borne by  the low- and middle-income countries  and disproportionately  affecting the 
lower socio-economic groups (29).       
 There were an estimated 40 million persons with diabetes in India in 2007 and this 
number is predicted to rise to almost 70 million people by 2025(30).
TYPE 2 DIABETES MELLITUS
Type  2  diabetes  is  the  most  common  form  of  diabetes.  It  is 
characterized  by  disorders  of  insulin  action  and  insulin  secretion,  either  of 
which  may  be  the  predominant  feature.  Although  the  specific  aetiology  of 
this  form of  diabetes  is  not  known,  autoimmune  destruction  of  the  β-cells 
does  not  occur. Most  patients  with  type  2  diabetes  are  obese  when  they 
develop diabetes,  and obesity  aggravates  the insulin  resistance.  The  risk  of 
developing  Type  2  diabetes  increases  with  age,  obesity,  and  physical 
inactivity.  Type  2  Diabetes  shows  strong  familial  aggregation,  so  that 
persons with a parent or sibling with the disease are at increased risk, as are 
individuals  with  obesity,  hypertension,  or  dyslipidemia  and  women  with  a 
history  of  gestational  diabetes.  Persons  of  Native  American,  Polynesian  or 
Micronesian,  Asian-Indian,  Hispanic,  or  African-American  descent  are  at 
higher risk than persons of European origin (1 ). Although the disease is most 
commonly  seen  in  adults,  the  age  of  onset  tends  to  be earlier  in  persons  of 
non-European  origin.  The  disease  can  occur  at  any  age  and  is  now seen  in 
children and adolescents (2 ,  3 ,  4 ,  and  5 ).
According to ADA 2008 guidelines:
2—Criteria for the diagnosis of diabetes:
1. FPG -126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 h.*
OR
2. Symptoms of hyperglycaemia and casual plasma glucose -200 mg/dl (11.1mmol/l). 
Casual is defined as any time of day without regard to time since last meal. The classic 
symptoms of hyperglycaemia include polyuria, polydipsia, and unexplained weight loss.
OR
3. 2-h plasma glucose -200 mg/dl (11.1 mmol/l) during an OGTT. The test
should be performed as described by the World Health Organization, using a
glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water*.
IMPAIRED GLUCOSE TOLERANCE (IGT)
IGT is  a  stage  of  impaired  glucose  regulation  that  is  present  in  individuals 
whose  glucose  tolerance  is  above  the  conventional  normal  range  but  lower 
than  the  level  considered  diagnostic  of  diabetes  (7 ,8 ). Cannot  be  defined  on 
the  basis  of  fasting  glucose  concentrations;  an  OGTT  is  needed  to 
categorize  such  individuals.  Persons  with  IGT  do  have  a  high  risk  of 
developing  diabetes,  although  not  all  do  so  (9 ).  Some  revert  to  normal 
glucose tolerance,  and others continue to have IGT for many years.  Persons 
with  IGT  have  a  greater  risk  than  persons  of  similar  age  with  normal 
glucose tolerance of developing arterial  disease  (10),  but they rarely develop 
the  more  specific  micro  vascular  complications  of  diabetes,  such  as 
retinopathy or nephropathy, unless they develop diabetes (7 ,11 ). 
……………..
*In the absence of unequivocal hyperglycemia, these criteria should be confirmed by 
repeat testing on a different day (6).
IMPAIRED FASTING GLUCOSE (IFG)
IFG  is  also  a  stage  of  impaired  glucose  homeostasis.  This  category 
was  introduced  in  the  1997  ADA and 1999  WHO classifications  to  include 
individuals whose fasting glucose levels were above normal but below those 
diagnostic for diabetes (7 ,  8 ).
Individuals  with  fasting  plasma  glucose  concentrations  of  100  to  125 
mg/dL are now considered to have IFG (12).  If  an OGTT is performed, some 
of  these  individuals  will  have  IGT  and  some  may  have  diabetes  (2  hours 
post  load  plasma  glucose  concentration  ≥200  mg/dL.  Consequently,  it  is 
prudent, and recommended by WHO, that such individuals, if possible, have 
an OGTT to exclude diabetes.
Table 1. Categories of hyperglycaemia (1 2 ):
Fasting plasma glucose level
Normala Impaireda Diabetes
2-Hour post load 
plasma glucose 
level
<100 mg/
dL
100–125 mg/
dL
≥126 mg/
dL Not done
<140 mg/dL Normal IFG Diabetes “Normal”
140–199 mg/dL IGT IFG/IGT Diabetes IGT
≥200 mg/dL Diabetes Diabetes Diabetes Diabetes
Not done “Normal” IFG Diabetes Unknown
Pathogenesis of Type 2 Diabetes mellitus:
Genetic factors: 
The  contribution  of  genetic  factors  to  the  development  of  insulin 
resistance,  impaired  insulin  secretion,  and  type  2  diabetes  has  been  known 
for many years (13 ,14) . Supporting evidence includes the familial clustering of 
these  traits  (13 ,14 ,15),  the  higher  concordance  rate  of  type  2  diabetes  in 
monozygotic versus dizygotic twins  (16 ,17 ,18 ) , and the high prevalence of type 
2  diabetes  in  certain  ethnic  groups. It  is  estimated  that  between  25%  and 
70%  of  the  occurrence  of  type  2  Diabetes  can  be  attributed  to  genetic 
factors  (18 ).  Studies  of  the  patterns  of  inheritance  indicate  that  multiple 
genes  probably  are  involved,  although  their  number  and  relative 
contributions are uncertain (19 ,20 ). 
Beta cell dysfunction: 
The distinctive β-cell  defect  in type 2 diabetes  is  the loss of  the first  phase 
of glucose-induced insulin secretion. The second phase is  also impaired but 
to  a  lesser  degree  (21 ,22).  Subsequent  investigation  showed  that  this  defect 
was  fully  established  by  the  time  the  fasting  glucose  level  reached  115 
mg/dL  (23 ) , clearly  predating  overt  diabetes,  but  was  not  present  in  persons 
with  truly  normal  glucose  levels  in  whom  type  2  diabetes  developed  later 
(24 ,25 ) . Thus,  it  first  appears  in  the  prediabetes  state,  termed  IGT,  which  is 
clinically manifest as excess postprandial excursions of glycaemia.
Insulin resistance:
The  term  insulin  resistance generally  refers  to  resistance  to  the 
metabolic  effects  of  insulin,  including the  suppressive  effects  of  insulin  on 
endogenous  glucose  production,  the  stimulatory  effects  of  insulin  on 
peripheral  (predominantly  skeletal  muscle)  glucose  uptake  and  glycogen 
synthesis, and the inhibitory effects of insulin on adipose tissue lipolysis.  It 
is  generally  accepted  that  insulin  resistance  plays  a  major  role  in  the 
development of type 2 diabetes.  Because currently an estimated 170 million 
people  worldwide  have  Type  2  Diabetes,  this  is  clearly  an  important 
association  (26).  Indeed,  prospective  studies  have  revealed  that  insulin 
resistance predates the onset of type 2 Diabetes by 10 to 20 years and is the 
best clinical predictor of subsequent development of type 2 Diabetes (27 ,  28).
Acquired factors:
• Beta cell  cytotoxic chemical/ virus.
• Autoimmunity.
• Ageing, obesity.
• TNF alpha, leptin.
• Physical inactivity.
• Diet.
Risk factors for Type2 Diabetes mellitus:
• Family history of diabetes
• Obesity
• Sedentary lifestyle
• IFG/ IGT
• History of GDM
• Systemic hypertension( >140/90 mm hg)
• HDL<35 mg/dl, TGL> 250 mg/dl
• Polycystic ovarian disease
• History of vascular disease
(Source: adopted from ADA 2004).
Complications of Diabetes mellitus (DM):
Acute Complications of DM
Diabetic ketoacidosis (DKA) and hyperglycaemic hyperosmolar state (HHS) are 
acute complications of diabetes. DKA was formerly considered a hallmark of type 1 
DM, but it also occurs in individuals who lack immunologic features of type 1 DM and 
who can subsequently be treated with oral glucose-lowering agents. HHS is primarily 
seen in  individuals  with type 2 DM. Both disorders  are  associated with absolute  or 
relative insulin deficiency,  volume depletion,  and acid-base abnormalities.  DKA and 
HHS exist along a continuum of hyperglycaemia, with or without ketosis (31).
Chronic Complications of DM-32
The chronic complications of DM affect many organ systems and are responsible 
for  the  majority  of  morbidity  and  mortality  associated  with  the  disease.  Chronic 
complications can be divided into vascular and nonvascular complications. The vascular 
complications  of  DM  are  further  subdivided  into  micro  vascular  (retinopathy, 
neuropathy,  nephropathy) and macro vascular  complications [coronary  artery disease 
(CAD),  peripheral  arterial  disease  (PAD),  cerebrovascular  disease].  Nonvascular 
complications include problems such as gastro paresis,  infections,  and skin changes. 
Long-standing diabetes may be associated with hearing loss. 
Evidence  implicating  a  causative  role  for  chronic  hyperglycaemia  in  the 
development  of  macro vascular  complications is  less  conclusive.  However,  coronary 
heart disease events and mortality are two to four times greater in patients with type 2 
DM. These events correlate with fasting and postprandial plasma glucose levels as well 
as with the A1C. Other factors (dyslipidemia and hypertension) also play important roles 
in macro vascular complications. 
                                    METABOLIC SYNDROME
The metabolic syndrome (syndrome X, insulin resistance syndrome) consists of a 
constellation  of  metabolic  abnormalities  that  confer  increased  risk  of  cardiovascular 
disease (CVD) and diabetes mellitus  (DM). The criteria  for  the metabolic syndrome 
have evolved since the original definition by the World Health Organization in 1998, 
reflecting growing clinical evidence and analysis by a variety of consensus conferences 
and professional organizations. The major features of the metabolic syndrome include 
central  obesity,  hypertriglyceridemia,  low  HDL  cholesterol,  hyperglycaemia,  and 
hypertension (33).
NCEP: ATPIII 2001 
Three or more of the following: 
• Central obesity: Waist circumference >102 cm (M), >88 cm (F).
• Hypertriglyceridemia: Triglycerides>150 mg/dL or specific medication.
• Low  HDL  cholesterol:  <40  mg/dL  and  <50  mg/dL  for  men  and  women 
respectively, or specific medication.
• Hypertension:  Blood pressure    > 130 mm systolic  or  > 85 mm diastolic  or 
specific medication.
• Fasting  plasma  glucose >100  mg/dL  or  specific  medication  or  previously 
diagnosed type 2 diabetes.
Table 2.  IDF Criteria for Central Adiposity:   Waist Circumference 
Men (cm) Women (cm) Ethnicity
94 80 Europid, Sub-Saharan African, Eastern & Middle Eastern
90 80 South Asian, Chinese, and ethnic South & Central American
85 90 Japanese
Two or more of the following: 
• Fasting triglycerides >150 mg/dL or specific medication.
• HDL cholesterol <40 mg/dL and <50 mg/dL for men and women, respectively, or 
specific medication.
• Blood  pressure >130  systolic  or  >85  mm  diastolic  or  previous  diagnosis  or 
specific medication.
• Fasting plasma glucose >100 mg/dL or previously diagnosed type 2 diabetes.
Epidemiology
Prevalence of the metabolic syndrome varies across the globe, in part reflecting 
the age and ethnicity of the populations studied and the diagnostic criteria applied. In 
general, the prevalence of metabolic syndrome increases with age. The highest recorded 
prevalence worldwide is in Native Americans, with nearly 60% of women ages 45–49 
and 45% of men ages 45–49 meeting National Cholesterol Education Program, Adult 
Treatment Panel III (NCEP:ATPIII) criteria.
Pathophysiology of the metabolic syndrome: 
Free  fatty  acids  (FFAs)  are  released  in  abundance  from an expanded  adipose 
tissue mass. In the liver, FFAs result in an increased production of glucose, triglycerides 
and secretion of  very low density  lipoproteins (VLDLs).  Associated lipid/lipoprotein 
abnormalities include reductions in high-density lipoprotein (HDL) cholesterol and an 
increased  density  of  low-density  lipoproteins  (LDLs).  FFAs  also  reduce  insulin 
sensitivity in muscle by inhibiting insulin-mediated glucose uptake. Associated defects 
include a reduction in glucose partitioning to glycogen and increased lipid accumulation 
in triglyceride (TG).  Increase in circulating glucose and to some extent FFA, increase in 
pancreatic insulin secretion, resulting in hyperinsulinemia. Hyperinsulinemia may result 
in  enhanced  sodium reabsorption  and  increased  sympathetic  nervous  system (SNS) 
activity and contribute to the hypertension, as might increase levels of circulating FFAs. 
The proinflammatory state is superimposed and contributory to the insulin resistance 
produced by excessive FFAs. The enhanced secretion of interleukin 6 (IL-6) and tumour 
necrosis  factor  (TNF-alpha)  produced  by  adipocytes  and  monocyte-derived 
macrophages  results  in  more  insulin  resistance  and  lipolysis  of  adipose  tissue 
triglyceride stores to circulating FFAs. IL-6 and other cytokines also enhance hepatic 
glucose production, VLDL production by the liver,  and insulin resistance in muscle. 
Cytokines and FFAs also increase the hepatic production of fibrinogen and adipocyte 
production of plasminogen activator inhibitor 1 (PAI-1), resulting in a prothrombotic 
state. Higher levels of circulating cytokines also stimulate the hepatic production of C-
reactive  protein  (CRP).  Reduced  production  of  the  anti-inflammatory  and  insulin 
sensitizing cytokine adiponectin are also associated with the metabolic syndrome.
Associated Diseases
• Cardiovascular Disease (33)
• The relative risk for new-onset CVD in patients with the metabolic syndrome, in 
the absence of diabetes, averages between 1.5- and threefold. In an 8-year follow-
up of middle-aged men and women in the Framingham Offspring Study (FOS), 
the  population  attributable  risk  for  patients  with  the  metabolic  syndrome  to 
develop CVD was 34% in men and 16% in women.
• Ischemic stroke.
• Peripheral vascular disease.
• Type 2 Diabetes
Overall, the risk for type 2 diabetes in patients with the metabolic syndrome is 
increased three- to fivefold. 
Other conditions associated with Metabolic Syndrome:
Increases in:
• ApoB and C III.
•  Uric acid- Hyperuricemia reflects defects in insulin action on the renal 
tubular reabsorption of uric acid.
• Prothrombotic factors (fibrinogen, plasminogen activator inhibitor 1).
•  Serum viscosity.
•  Asymmetric dimethylarginine, homocysteine, white blood cell count, pro-
inflammatory cytokines, CRP.
•  Microalbuminuria.
• Non-alcoholic  fatty  liver  disease  (NAFLD)  and/or  non-alcoholic 
steatohepatitis (NASH).
• Polycystic ovarian disease (PCOS).
• Obstructive sleep apnoea (OSA).
OBESITY
Obesity  is  defined  as  a  state  of  excessive  adipose  tissue  mass  and  is 
best  viewed  as  a  syndrome  or  group  of  diseases  rather  than  as  a  single 
disease entity. The importance of this state derives from its high prevalence 
in  our  society  and  its  association  with  serious  morbidity,  not  the  least  of 
which is a marked increase in the prevalence of type 2 diabetes.
 BMI  is  calculated  by  determining  weight  in  kilograms  and  dividing 
by the height  in  meters  squared.  This  measurement  has been used to  define 
four classes of body weight. A BMI of 
• < than 18.5 is considered underweight . 
•  18.5 - 24.9 is considered normal. 
•  25.0 - 29.9 is considered overweight or preobese. 
• > 30 is considered in the obese category.
 class I (BMI, 30 to 39.9)
 class II (BMI, 40 to 49.9) 
 class III (BMI, >50).
The definition of obesity can be refined on the basis of the realization 
that  the  accumulation  of  adipose  tissue  in  different  depots  has  distinct 
consequences.  Thus,  many  of  the  most  important  complications  of  obesity, 
including insulin resistance, diabetes, hypertension, and hyperlipidemia, are 
linked  to  the  amount  of  intraabdominal  fat,  rather  than  to  lower-body  fat 
(i.e., buttocks and leg) or subcutaneous abdominal fat  (34 ,  35).  Abdominal fat, 
typically evident  on physical examination,  can be estimated by determining 
the  waist-to-hip  circumference  ratio  (with  a  ratio  >0.72  considered 
abnormal),  or  more  accurately  quantified  by  dual-energy  x-ray 
absorptiometry (DEXA) scanning or computed tomography.
An important  predictor  of  the morbidity  and mortality  associated with 
obesity is the quantity of visceral fat. A rough index of the relative amounts 
of  visceral  and  abdominal  fat  is  the  waist-to-hip  ratio.  The  alternative 
patterns  of  body-fat  distribution  have  been  described  as  pear  shaped  (low 
waist-to-hip  ratio)  and  apple  shaped  (higher  waist-to-hip  ratio).  When  the 
waist-to-hip ratio is less than 0.8, the relative risk of morbidities associated 
with  obesity  is  lower  than  when  the  waist-to-hip  ratio  is  greater  than  1.0. 
Hence,  the  metabolic  syndrome,  which  is  a  clustering  of  obesity  and  other 
cardiovascular  risk  factors,  is  more  likely  to  be  associated  with  visceral 
obesity (36).
PATHOLOGIC CONSEQUENCES OF OBESITY:
• Diabetes
The  increased  risk  for  type  2  diabetes  in  individuals  with  obesity  is 
considerable  (37 ).  In  persons  aged  20  to  44,  obesity  is  associated  with  a 
fourfold  increase  in  the  relative  risk  of  diabetes. Potential  candidate 
substances produced by fat that may cause insulin resistance include tumour 
necrosis  factor  and  other  cytokines,  such  as  interleukin-6,  and  resistin  and 
adiponectin.
• Cardiovascular Disease
Obesity  is  an  independent  risk  factor  for  cardiovascular  disease  (38 ), 
including coronary  artery disease and congestive  heart  failure,  in  both men 
and women.
• Pulmonary disease:
The increased metabolic rate in obese subjects increases O 2 consumption 
and  CO2 production,  and  these  changes  result  in  increased  minute 
ventilation.  In  subjects  with  marked  obesity,  the  compliance  of  the  chest 
wall  is  reduced,  the  work  of  breathing  is  increased,  and  the  respiratory 
reserve volume and vital capacity are reduced (39 ,  40).
• Gallstones. 
Increased incidence of cholesterol gallstones (41).
• Cancer:  The  relative  risk  of  liver  cancer  was  almost  2-fold  higher  in 
men  with  a  BMI  of  30.0  to  34.9.  In  men  with  a  BMI  higher  than  35, 
the  risk  of  stomach  cancer  was  increased  1.94-fold,  that  of  kidney 
cancer  was  increased  1.7-fold,  and  that  of  oesophageal  cancer  was 
increased  1.6-fold  over  the  risk  in  normal-weight  individuals.  In 
women with  a  BMI  greater  than  35,  the  relative  risk  of  cancer  of  the 
uterus  was  2.8,  of  cancer  of  the  cervix  was  3.8,  and  of  breast  cancer 
was 1.7 (42).
• Hyperinsulinemia.
Major cardiovascular risk factors indicated in JNC-7 report are:
• Hypertension
• Smoking
• Obesity
• Physical inactivity
• Diabetes mellitus
• Dyslipidemia
• Microalbuminuria or estimated GFR< 60ml/mt
o Age> 55 for men, 
o >65 for women
• Family history of premature cardiovascular disease
o <55 for men
o <65 for women.
URIC ACID
Uric acid is  a  weak acid  trioxypurine with a  molecular  weight  of  168 that  is 
composed  of  a  pyrimidine  and  imidazole  substructure  with  oxygen  molecules.  It  is 
produced  during  the  metabolism  of  purines,  and  specifically,  is  generated  by  the 
degradation  of  xanthine  by  the  enzyme  xanthine  oxidase  or  its  isoform,  xanthine 
dehydrogenase.
Generation of Uric Acid:
Uric acid is produced from metabolic conversion of either dietary or endogenous 
purines, primarily in the liver, muscle, and intestine. The immediate precursor of uric 
acid  is  xanthine,  which  is  degraded  to  uric  acid  by  either  xanthine  oxidase,  which 
generates superoxide anion in the process, or by its isoform, xanthine dehydrogenase, 
which generates the reduced form of nicotinamide-adenine dinucleotide. (Figure 1).
           
      Figure 1:     URIC ACID SYNTHESIS FROM PURINES
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Both exogenous purines (such as is present in fatty meat, organ meats, and seafood) and 
endogenous purines are major sources of uric acid in humans.
   
Figure 2: Uric acid metabolism
Excretion of Uric Acid:
The primary site of excretion of uric acid is the kidney, with normal urinary urate 
excretion in the range of 250 to 750 mg per/day. Although urate (the form of uric acid at 
blood pH of 7.4) is freely filtered in the glomerulus, there is evidence that there is both 
reabsorption and secretion in the proximal tubule, and as a consequence the fractional 
urate excretion is only 8% to 10% in the normal adult. In addition, some excretion of 
uric acid occurs through the gut, where uric acid is degraded by uricolytic bacteria, and 
this may account for one-third of the elimination of uric acid in the setting of renal 
failure. 
Uric  acid  excretion  consists  of  a  four-step  model  with  glomerular  filtration, 
followed  by  reabsorption,  secretion,  and  postsecretory  reabsorption,  the  latter  three 
processes all occurring in the proximal convoluted tubule. (43, 44).
In the human kidney, urate is transported via URAT-1 across the apical membrane 
of proximal tubular cells, in exchange for anions being transported back into the tubular 
lumen  to  maintain  electrical  balance.  Pyrazinamide,  probenecid,  losartan,  and 
benzbromarone all inhibit urate uptake in exchange for chloride at the luminal side of 
the cell by competition with the urate exchanger.
Urate secretion appears to be mediated principally by a voltage-sensitive urate 
transporter,  which  is  expressed  ubiquitously  and  localizes  to  the  apical  side  of  the 
proximal tubule in the kidney. The primary candidate is urate transporter (UAT), which 
is in the galactin family (45).  Recently, a novel human renal apical organic anion efflux 
transporter, called MRP4, has been identified. MRP4 is a member of the ATP-binding 
cassette transporter family (46).
HYPERURICEMIA
Hyperuricemia has been arbitrarily defined as >7.0 mg/dL in men and >6.5 mg/dL 
in women  (109). Uric acid levels tend to be higher in certain populations (e.g., African 
American and Pacific Islanders), with certain phenotypes (obesity, metabolic syndrome) 
and with special diets (meat eaters vs. vegetarians)  (47). Uric acid also has a circadian 
variation, with the highest levels in the early morning (48). The serum urate concentration 
reflects the balance between urate production and elimination. Hyperuricemia may occur 
from  excessive  production  of  urate  (overproduction)  or  decreased  elimination 
(underexcretion),  and frequently  a  combination of  both processes occur  in  the same 
patient. Furthermore, uric acid levels may vary in the same individual by as much as 1 to 
2 mg/dL during the course of a day, due to the effects of diet and exercise.
Major causes of Hyperuricemia
Genetic causes (49)
 Familial hyperuricemic nephropathy (mutation of uromodulin).
 Lesch-Nyan syndrome (HGPRT mutation).
 Phosphoribosyl pyrophosphate synthetase (PRPPS) mutation.
Dietary causes 
• Diet high in purines (organ meats, shellfish, fatty meats).
• Diet high in fructose (high fructose corn syrup, table sugar, honey).
• Ethanol.
• Low salt diet.
Drugs
 Thiazides.
 Loop diuretics.
 Calcineurin inhibitors (cyclosporine > tacrolimus).
 Pyrazinamide.
 Low-dose aspirin.
Volume depletion.
Hypoxia (systemic or tissue).
Increased cell turnover (myeloproliferative disorders, polycythemia vera).
Conditions associated with higher uric acid levels:
   Renal failure.
   Obesity/metabolic syndrome.
  Untreated hypertension.
   African American race.
   Preeclampsia.
  Vigorous exercise.
The following abnormalities are commonly associated with but not causally 
related to Hyperuricemia.
• Obesity
• Insulin resistance
• Dyslipidemia ( usually type 4 with increased VLDL and normal cholesterol).
• Hypertension
• Ischemic heart disease.
HYPOURICEMIA:
Low uric acid levels (levels <2.0 mg/dL) can occur via a variety of mechanisms 
(49).
Causes of Hypouricemia:
Liver disease
Fanconi's syndrome
Diabetes (with glycosuria)
Inappropriate secretion of vasopressin
Familial hypouricemia (due to URAT-1 mutation)
Total parenteral hyperalimentation
Medications with uricosuric property including aspirin (>2.0g/day), x-ray 
contrast materials, ascorbic acid, calcitonin, outdated tetracycline and 
glyceryl guaiacolate.
Uric acid and Hypertension, the metabolic syndrome and cardiovascular disease.
Studies such as  the Framingham analysis  published in 1999 reported that  this 
relationship of uric acid with cardiovascular disease was not independent when it was 
controlled for other accepted cardiovascular risk factors, such as hypertension, diuretic 
use, obesity, and renal disease  (50).  Most societies concluded that there is insufficient 
evidence to support uric acid as a true cardiovascular risk factor.
Hyperuricemia and hypertension:
Recent studies have provided provocative data that uric acid may be a true risk 
factor for hypertension. Thus, an elevated serum uric acid is now recognized to be an 
independent risk factor for the development of hypertension  (51). This has been shown by 
multiple groups including a recent analysis by the Framingham group (52). Furthermore, 
an elevated serum uric acid is common in subjects with new-onset hypertension.
Hyperuricemia is also more common in primary hypertension than in secondary 
hypertension, at least in adolescents  (64). In one study an elevated uric acid level (>5.5 
mg /dl) was observed in nearly 90% of adolescents with essential hypertension, whereas 
uric acid levels were significantly lower in controls and teens with either white-coat or 
secondary  hypertension  (64).  Interestingly,  the  relationship  of  uric  acid  levels  to 
hypertension  in  people  with  established  hypertension  varies.  In  some  studies 
hyperuricemia is present in 40 to 60% of subjects with untreated hypertension  (65,66,69) 
whereas other studies reported lower frequencies (65,67). Some of the variability might be 
due to the inclusion of patients with secondary hypertension in various reports. Potential 
mechanisms involved with the association of hyperuricemia and hypertension include 
the following:
1. Decreased renal blood flow (decreased GFR) stimulating urate reabsorption, 
2. Microvascular (capillary) disease resulting in local tissue ischemia. 
3.  Ischemia  with  associated  increased  lactate  production  that  blocks  urate 
secretion in the proximal tubule and increased uric acid synthesis due to increased 
RNA-DNA breakdown and increased purine (adenine and guanine) metabolism, 
which increases uric acid and ROS through the effect of xanthine oxidase (XO). 
4. Ischemia induces increased XO production and increased SUA and ROS. 
These associations with ischemia and XO induction may help to understand why 
hyperuricemia is associated with preeclampsia and congestive heart failure.
Uric acid, Metabolic Syndrome, Type 2 diabetes and Atheroscleropathy:
Glucotoxicity places an additional burden of redox stress on the arterial vessel 
wall  and  capillary  endothelium.  Hyperglycemia  induces  both  an  oxidative  stress 
(glucose autoxidation and advanced glycosylation endproducts (AGE) – ROS oxidation 
products)  and  a  reductive  stress  through  pseudohypoxia  with  the  accumulation  of 
NADH and NAD(P)H in the vascular intima (70,71,72).
This redox stress consumes the natural occurring local antioxidants such as: SOD, 
GPX, and catalase.  Once  these  local  intimal  antioxidants  are  depleted uric  acid can 
undergo the paradoxical antioxidant – prooxidant switch or the urate redox shuttle (73,74).
New studies have also suggested that hyperuricemia may have a pathogenetic role 
in the obesity metabolic syndrome. Thus, an elevated uric acid was found to predict the 
development  of  both obesity  and hyperinsulinemia in  normal  subjects  (53,54,55) and an 
elevated uric acid is universally present in the metabolic syndrome  (56). The low nitric 
oxide may also have a central role in the induction of insulin resistance, since insulin 
requires nitric oxide for its action (by stimulating blood flow to the skeletal muscle).
Hyperinsulinemia:
Insulin, proinsulin, and amylin individually and synergistically activate the renin 
– angiotensin system (RAS) with subsequent increase in Angiotensin II. Angiotensin II 
is  the  most  potent  endogenous  inducer  of  NAD(P)H oxidase,  increasing  NAD(P)H, 
which increases vascular – intimal reactive oxygen species (ROS) and superoxide (O2-•) 
(70,75).
Obesity:
Leptin levels are elevated and associated with insulin resistance in MS and early 
T2DM. Bedir A  et al.  have recently discussed the role of leptin as possibly being a 
regulator of SUA concentrations in humans and even suggested that leptin might be one 
of the possible candidates for the missing link between obesity and hyperuricemia  (76). 
Furthermore,  hypertriglyceridemia  and  free  fatty  acids  are  related  to  hyperuricemia 
independently of obesity and central body fat distribution (77,78).
Prothrombotic milieu:
In MS and T2DM there is an observed increased thrombogenecity, hyperactive 
platelets, increased PAI-1 (resulting in impaired fibrinolysis), and increased fibrinogen 
in the atherosclerotic milieu associated with the dysfunctional endothelial cell. 
Uric acid and cardiovascular disease:
The mechanism by which uric acid may cause cardiovascular disease has been 
explored using both cell culture and animal models. It appears that uric acid must enter 
the endothelial and vascular smooth muscle cell via a specific organic anion exchanger, 
where  it  activates  a  variety  of  intracellular  signalling  molecules  involved  in 
inflammation and proliferation. In the endothelial cell there is a decrease in nitric oxide 
levels  and an inhibition of  endothelial  proliferation,  whereas in  the vascular  smooth 
muscle  cell  there  is  activation  of  proliferative  and  inflammatory  pathways. 
(57,58,59,60,61,62,63).
Uric acid and endothelial dysfunction:
The upper 1/3 of the normal physiologic – homeostatic range (> 4 mg/dl) and 
abnormal elevations (> 6.5 or  7 mg/dl  in men and > 6.0 mg/dl  in women) in SUA 
definitely should be considered as one of the multiple injurious stimuli to the arterial 
vessel wall and capillary, which may contribute to endothelial dysfunction and arterial – 
capillary vessel wall remodelling through oxidative – redox stress (70, 79,80).
SUA in  the  early  stages  of  the  atherosclerotic  process  is  known to  act  as  an 
antioxidant  and  may  be  one  of  the  strongest  determinates  of  plasma  antioxidative 
capacity (81).
However, later in the atherosclerotic process when SUA levels are known to be 
elevated (in the upper 1/3 of the normal range >4 mg/dl and outside of the normal range 
>6  mg/dl  in  females  and  6.5–7  mg/dl  in  males)  this  previously  antioxidant  (SUA) 
paradoxically becomes prooxidant. This antioxidant – prooxidant urate redox shuttle 
seems to rely heavily on its surrounding environment such as timing (early or late in the 
disease process), location of the tissue and substrate, acidity (acidic – basic – or neutral 
ph), the surrounding oxidant milieu, depletion of other local antioxidants, the supply and 
duration of oxidant substrate and its oxidant enzyme. In the accelerated atherosclerotic – 
vulnerable  plaque  the  intima  has  been  shown  to  be  acidic  (82),  depleted  of  local 
antioxidants with an underlying increase in oxidant stress and ROS  and associated with 
uncoupling  of  the  eNOS  enzyme  and  a  decrease  in  the  locally  produced  naturally 
occurring antioxidant: eNO and endothelial dysfunction.
Uric acid has been found to promote low-density lipoprotein (LDL) oxidation in 
vitro, a key step in the progression of atherosclerosis (86),  and these effects are inhibited 
by vitamin C (87) indicating an important interaction between aqueous anti-oxidants. Uric 
acid can also stimulate granulocyte adherence to the endothelium (88), and peroxide and 
superoxide free radical liberation (89). Uric acid traverses dysfunctional endothelial cells 
and accumulates as crystal within atherosclerotic plaques (91).
Endothelial function and endothelial nitric oxide (eNO)
Endothelium is responsible for  regulation of vascular tone, inflammation, lipid 
metabolism,  vessel  growth  (angiogenesis  –  arteriogenesis),  arterial  vessel  wall  – 
capillary  sub  endothelial  matrix  remodelling,  and  modulation  of  coagulation  and 
fibrinolysis. One particular enzyme system seems to act as the maestro: The endothelial 
nitric  oxide  synthase  (eNOS)  enzyme  and  its  omnipotent  product:  endothelial  nitric 
oxide (eNO) .
The  endothelial  nitric  oxide  synthase  (eNOS)  enzyme  reaction  is  of  utmost 
importance to the normal functioning of the endothelial cell and the intimal interstitium. 
When  this  enzyme  system  uncouples  the  endothelium  becomes  a  net  producer  of 
superoxide  and  ROS  instead  of  the  net  production  of  the  protective  antioxidant 
properties of eNO.
The activated, dysfunctional endothelium is a net producer of superoxide (O2-) 
associated with MS, T2DM, and atheroscleropathy (83).
Uric acid is known to induce the nuclear transcription factor (NF-kappaB) and 
monocyte chemo attractant protein-1 (MCP-1)  (84).  Regarding TNF alpha it has been 
shown  that  SUA  levels  significantly  correlate  with  TNF  alpha  concentrations  in 
congestive heart failure and as a result Olexa P et al. conclude that SUA may reflect the 
severity  of  systolic  dysfunction  and  the  activation  of  an  inflammatory  reaction  in 
patients with congestive heart failure [85]. Additionally, uric acid also stimulates human 
mononuclear cells to produce interleukin-1 beta, IL-6, and TNF alpha (86).
SUA may or may not be an independent risk factor especially since its linkage to 
other risk factors is so strong, however there is not much controversy regarding its role 
as a marker of risk, or that it is clinically significant and relevant.
                                 
MATERIALS AND METHODS
Setting                                       : Government Royapettah Hospital, Chennai.
Collaborative Department      : Department of Biochemistry, GRH.
Study Design                            : Descriptive analytical study.
Period of Study                        : February 2008 to March 2009.
Sample Size                              : 70 cases.
 Inclusion criteria:
1. Patients with type 2 diabetes mellitus (irrespective of their glycemic status and 
duration of diabetes).
2. Patient’s age > 40 years.
3. Both sexes were included.
Exclusion criteria:
Patients with
1. Renal failure.
2. On long term diuretics and steroids.
3. Regularly consuming alcohol.
4. On antimetabolite and chemotherapy drugs.
5. Hepatic disorders.
6. Peripheral vascular disease/ cerebrovascular disease/ pulmonary tuberculosis.
7. Renal transplant patients.
8. Pregnancy and lactating mothers.
Cases:  
Diabetics with age greater than 40 years and of both sexes were included. Cases 
were selected after considering the exclusion criteria.
Controls: 
Subjects who were above 40 years and who had normal blood sugar and who met 
the above exclusion criteria are kept as controls.
Consent:
The study group thus identified were instructed about the nature of the study. 
Willing  participants  were  included in  this  study  after  getting  their  written  informed 
consent.
Materials: 
A total of 70 cases who satisfied the inclusion and exclusion criteria above were 
taken up for the study. Thirty age and sex matched subjects were kept as controls.
Conflict of interest:
There was no conflict of interest.
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Limitations:
• Because of limited resources GTT, HbA1c, leptin levels, C peptide assay, 
plasma insulin assay could not be done.
• Because of limited resources urinary uric acid excretion and urate clearance 
could not be done.
Methods:
Selected  data  were  elicited  from  the  patients  and  controls  and  recorded  in 
proforma.
1. Socio demographic data:
• Age
• Sex
2. Clinical  data:
• Body weight, height, BMI.
• WHR.
• Systolic and Diastolic blood pressure.
• Duration of diabetes.
• Family history of diabetes.
• Smoking history.
• Ischemic heart disease.
• Fundus examination.
• Neurological examination for peripheral neuropathy.
3. Laboratory  data:
• Fasting  and  postprandial  blood  sugar  levels  estimated  by  using 
glucosoxidase-peroxidase (GOD/POD) method.
• Serum lipid profile.
• Blood  urea  estimation  was  done  manually  by  using  diacetyl  monoxime 
method (DAM).
• Serum creatinine estimation was done by using alkaline picrate method.
• Serum uric acid was done by using phosphotungstic acid method.
Principle:
Step 1: Deproteinisation: In a test tube to 1 ml of distilled water, 0.2 ml of serum, 
0.4 ml of 2/3 N H2SO4, 0.4 ml sodium turgitate(10%) are added and sample centrifuged 
for 5 minutes.
Step 2: To 1 ml of the filtrate add 0.75N NaOH, saturated picric acid 0.5 ml mix 
well & wait for 15 minutes. Reading is taken at 490 nm calorimetrically.
Statistical Analysis:
Data  was  entered  in  Microsoft  Excel  Spreadsheet  and  analysed.  Significance 
values were analysed using standard SPSS software. Student‘t’ values was applied for 
significance. Significance was considered, if the ‘p’ value was below 0.05.
DEFINITIONS USED IN THE PRESENT STUDY
Diabetes Mellitus:
1. FPG -126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 h.*
OR
2. Symptoms of hyperglycaemia and casual plasma glucose -200 mg/dl (11.1mmol/l). 
Casual is defined as any time of day without regard to time since last meal. The classic 
symptoms of hyperglycaemia include polyuria, polydipsia, and unexplained weight loss.
OR
3. 2-h plasma glucose -200 mg/dl (11.1 mmol/l) during an OGTT. The test
should be performed as described by the World Health Organization, using a
glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water. *
Hyperuricemia:
Hyperuricemia has been arbitrarily defined as >7.0 mg/dL in men and >6. mg/dL in 
women. 
………………
*In the absence of unequivocal hyperglycemia, these criteria should be confirmed by 
repeat testing on a different day (6).
Body Mass Index (BMI):
It is estimated by using the formula: 
BMI=Weight (kg)/ height² (m)
Obesity:
. A BMI of 
• < than 18.5 is considered underweight . 
•  18.5 - 24.9 is considered normal. 
•  25.0 - 29.9 is considered overweight or preobese. 
• > 30 is considered in the obese category.
 class I (BMI, 30 to 39.9)
    class II (BMI, 40 to 49.9) 
 class III (BMI, >50).
  Metabolic syndrome:
  The criteria for the metabolic syndrome have evolved since the original definition 
by the World Health Organization in 1998,  reflecting growing clinical  evidence and 
analysis by a variety of consensus conferences and professional organizations. 
NCEP:ATPIII 2001 
Three or more of the following:
Central obesity: Waist circumference >102 cm (M), >88 cm (F).
Hypertriglyceridemia: Triglycerides >150 mg/dL or specific medication.
Low HDL cholesterol: <40 mg/dL and <50 mg/dL in men and women respectively, or 
specific medication.
Hypertension:  Blood  pressure    >130 mm systolic  or  >85  mm diastolic  or  specific 
medication.
Fasting plasma glucose >100 mg/dL or specific medication or previously diagnosed type 
2 diabetes.
Waist hip ratio:
The waist is measured by taking a circumference that gives the narrowest measurement 
between the ribcage and the iliac crest. The hip measurement is taken by measuring at a 
level that gives the maximal measurement of hip over the buttocks. It is a simple method 
that is unrelated to height, correlates closely with body mass index. Waist hip ratio is an 
approximate index of intra abdominal fat mass and total body fat.
Waist hip ratio >0.9 in women and >1.0 in men is abnormal.
Conversion of blood glucose to plasma glucose:
John Neale (1999) described the conversion of blood glucose to plasma glucose by using 
the formula:
              Plasma glucose= Whole blood glucose × 1.12
RESULTS
The total number of subjects included in this study was 100. Among them 70 were 
cases (type 2 diabetes mellitus) and 30 were controls (non diabetics).  The details  of 
subjects included in this study are given table 3.
TABLE 3: DETAILS OF THE SUBJECTS INCLUDED IN THE STUDY
Parameters Cases Controls
Total No. 70 30
Gender M= 42   F= 28 M= 16   F= 14
Age (Yrs) 43-79 41-76
Mean Age (Yrs) 59.55 55.8
BMI 18.4-29.4 18.6-26.2
WHR 0.76-1.14 0.65-1.12
FBS(mg/dl) 102-206 86-129
PBS (mg/dl) 162-304 123-198
SUA (mgt/dl) 3.3-8.2 2.6-5.3
Analysis of cases and controls with respect to age:
Mean and standard deviation for age of the cases and controls were 59.55±8.69 
and 55.8 ±8.96 respectively; there was no significant difference among the cases and 
controls with reference to the age. The distribution of cases and controls in relation to 
age is provided in table 4.
TABLE 4: CASES AND CONTROLS IN RELATION TO DIFFERENT
AGE GROUPS
* p= 0.058 (not significant)
The age group of the case and control group did not vary significantly.
Analysis of cases and controls with respect to gender:
Among  70  cases  studied,  there  were  42  males  and  28  females.  Among  30 
controls, there were 16 males and 14 females. The details are given in table 5.
TABLE 5: CASES AND CONTROLS IN RELATION TO GENDER
Sex
Cases* Controls
No. % No. %
Male 42 65.71 16 53.33
Female 28 34.29 14 46.67
Total 70 100.00 30 100.00
*P= 0.6986 (not significant)
The sex composition of the study and control group did not differ significantly.
Analysis of cases and controls with respect to B.M.I:
The mean and standard deviation foe the cases and controls were 24.38±2.8 and 
22.07±2.23 respectively. The details are shown in table 6.
TABLE 6:  CASES AND CONTROLS WITH RESPECT TO BMI
BMI Cases* Controls
No. % No. %
<25 37 52.86 26 86.67
>25 33 47.14 4 13.33
Total 70 100.00 30 100.00
Mean 24.38 22.07
SD 2.80 2.23
p = 0.0028
The BMI of the study group was significantly higher than that of the control group. 
Blood sugar distribution among cases: 
The details of fasting and post prandial blood sugar distribution among cases are 
shown in the table 7. The mean and Standard deviation for fasting blood sugar was 
144.3±23.38 while the mean and Standard Deviation for post prandial blood sugar was 
214.70± 32.11.This shows that the diabetic status was under poor control among cases.
TABLE 7: 
FASTING AND POST PRANDIAL BLOOD SUGAR LEVELS AMONG CASES (N=70)
*p 0.0001 
Analysis of cases and controls in relation to selected cardiovascular risk factors: 
Details of the analysis of cases and controls in relation to selected cardiovascular 
risk factors are provided in Table 8. 
TABLE 8: ANALYSIS OF CASES AND CONTROLS IN RELATION TO SELECTED 
CARDIOVASCULAR RISK FACTORS
Risk factor Cases* ControlsNo. % No. % P value
Family history 
YES 13 18.57 6 20.00
NO 57 81.43 24 80.00
0.9114
(ns)
Total 70 100.00 30 100.00  
Smoking among males 
YES 18 42.86 4 25.00
NO 24 57.14 12 75.00
0.3421
(ns)
Total 42 100.00 16 100.00  
Hyper tension
YES 18 25.71 8 26.67
NO 52 74.29 22 73.33
0.8813
(ns)
Total 70 100.00 30 100.000
0
 
There was no significant difference between cases and controls in relation to selected 
cardiovascular risk factors.
Distribution of cases and controls in relation to serum uric acid:
Mean serum uric acid in the study population was 5.26±1.39. Mean serum uric acid in 
the control group was 3.54±0.62. The details are shown in the table 9.
TABLE 9: 
GENDERWISE SERUM URIC ACID LEVEL IN DIABETICS AND CONTROLS
The serum uric  acid  levels  in  diabetics  were  very  much  high when compared  with 
controls and it was highly significant.
Analysis of gender distribution with serum uric acid among the cases:
The mean serum uric acid value in males was 5.45±1.47 whereas in females it 
was 4.97±1.23.The details are shown in table 10.
TABLE 10: 
SERUM URIC ACID VALUES IN RELATION TO SEX
In the study group mean serum uric acid values were higher in males than in 
females but the difference was not statistically significant (Table 10).
Analysis of hyperuricemia in cases and controls: 
Hyperuricemia is defined as serum uric acid level ≥7mg/dl in males and ≥6.5 mg/
dl in females. 
TABLE 11: 
HYPERURICEMIA AMONG DIABETICS AND CONTROLS
Hyperuricemia Cases* Controls
No. % Mean SD No. % Mean SD
Positive 8 11.43 7.675 0.615 0 - - -
Negative 62 88.57 4.94 1.129 30 100 3.54 0.62
* p =   0.0001 (significant)
The results are presented in table 11 which indicate that the prevalence of hyperuricemia 
was more in diabetic patients when compared to controls.
Body Mass Index (BMI)
 TABLE 12: 
SERUM URIC ACID VALUES WITH REGARD TO BMI AMONG CASES
The mean value of serum uric acid was 6.4±1.01 in those with BMI > 25. The 
mean value of serum uric acid was 4.23±0.72 in those with BMI < 25. The details are 
shown in table 12. Mean uric acid was positively correlating with BMI.
Serum uric acid value in relation to waist hip ratio (WHR):
Uric acid level increases with increasing WHR. WHR was considered abnormal if 
≥1.0 in men, ≥0.9 in females.
Thirty six cases with abnormal WHR had mean uric acid values 5.92±1.31.
Thirty four cases with normal WHR had mean uric acid values 4.55±1.11. The 
details are shown in table 13. 
 TABLE 13: 
WAIST HIP RATIO AND HYPERURICEMIA
Mean 
serum uric acid levels were positively correlating with WHR.
Smoking and serum uric acid among the cases (only in males):
The mean value of serum uric acid level in smokers was 5.07±1.119, while it was 
5.73+1.65 among non-smokers (Table 14). 
TABLE 14: 
URIC ACID LEVELS IN RELATION TO SMOKING 
(ONLY IN MALES)
The difference was not statistically significant.
Serum uric acid values in hypertensive patients:
The total number of hypertensive in the cases group was 18.
The details are shown in table 15.
TABLE 15: 
SERUM URIC ACID VALUES IN RELATION TO HYPERTENSION
Hypertension No. of Cases Serum uric acid values
Mean SD
p value
YES 18 6.60 1.105
NO 52 4.79 1.18
0.0001
The mean serum uric acid level in the hypertensive group was 6.60±1.105.The 
mean serum uric acid level in the non hypertensive group was 4.79±1.18. The difference 
between the two groups was statistically significant (Table 15).
Serum uric acid in relation to lipid profile abnormality:
The  mean  serum  uric  acid  in  patients  with  lipid  profile  abnormality  was 
6.37±1.02. The mean serum uric acid in patients without lipid profile abnormality was 
4.79±1.18. The details are shown in table 16.
TABLE 16: 
SERUM URIC ACID VALUES IN RELATION TO 
LIPID PROFILE ABNORMALITY (LPA)
LPA
No.    of 
Cases
Serum uric acid values
Mean SD
P value
YES 26 6.37 1.02
NO 44 4.60 1.14
0.0001
The difference between the two groups was statistically significant. (Table 16).
Gender wise Serum triglyceride level among cases:
The serum triglyceride level in males was 149.81±26.83. The serum triglyceride 
level  in females was 154.65±29.37.  The difference between the two groups was not 
statistically significant (Table 17).
Table 17:  Gender wise serum triglyceride values among cases
Sex
Serum triglycerides
Mean SD
P value
Male 149.81 26.83
Female 154.65 29.37
0.488 (NS)
CAD and Hyperuricemia: 
Number of patients with ischemia- 14. 
The mean serum uric acid level in ischemia group was 6.75±1.203. Of   this only 5 had 
hyperuricemia which includes 4 males and 1 female.
Number of patients with infarction- 4.
The mean serum uric acid level in infarction group was 7.3±0.96. Of this only 2 had 
hyperuricemia which includes 1 male and 1 female.
Percentage of hyperuricemia in infarction (50%) is higher than in ischemia (35.71%). 
The details are shown in tables 18&19.
         TABLE 18: CAD VS SERUM URIC ACID VALUES
CAD
No. of 
patients
Serum uric acid values
Mean SD
p value
Ischemia 14 6.75 1.203
Infarction 4 7.3 0.96
0.391 (ns)
TABLE 19: CAD AND HYPERURICEMIA
CAD
No. of 
patients
Total no. of 
hyperuricemia
Sex %
Male Female
Ischemia 14 5 4 1 35.71
Infarction 4 2 1 1 50.00
Percentage of hyperuricemia in infarction (50%) is higher than in ischemia (35.71%). 
The details are shown in tables 18&19.
Serum Uric acid in relation to duration of diabetes: 
MEAN SERUM URIC ACID LEVEL IN LONGER DURATION
Mean serum uric acid level  in longer duration (8-12 years)  diabetes  was 6.47 
±1.07.  Mean serum uric acid level  in shorter duration (2-4 years) diabetes was 4.30 
±0.77. The details are shown in table 20.
TABLE 20: 
DURATION OF DIABETES (DOD) AND HYPERURICEMIA
DOD * 
(Years) No. of patients
Hyperuricemia
Mean SD
2-4 12 4.30 0.77
5-8 31 4.57 1.01
9-12 27 6.47 1.07
*      2-4 vs. 5-8   yrs ----- p = 0.356 (ns)
2-4 vs. 9-12 yrs ----- p = 0.0001
      5-8 vs. 9-12 yrs ----- p = 0.0001
Uric acid level increases with increasing duration of diabetes and it  was statistically 
significant.
 DISCUSSION
An  epidemiological  link  between  elevated  serum  uric  acid  and an  increased 
cardiovascular risk has been recognized for many years. Observational studies show that 
serum uric acid concentrations are higher in patients with established coronary heart 
disease compared with healthy controls. However, hyperuricemia is also associated with 
possible  confounding factors  including  elevated  serum  triglyceride  and  cholesterol 
concentrations,  blood  glucose,  fasting  and  post-carbohydrate plasma  insulin 
concentrations, waist-hip ratio and body mass index.
There are  certain clinical  clustering groups with increased cardiovascular  risk, 
which have associated hyperuricemia. 
• Non-diabetic patient groups with accelerated atherosclerosis,
• T2DM patient groups with accelerated atherosclerosis,
• Congestive heart failure patient groups with ischemic cardiomyopathy, metabolic 
syndrome patients,
• Renal disease patient groups,
• Hypertensive patient groups, 
• African American patient groups, 
• Patient groups taking diuretics, 
• Patient groups with excessive alcohol usage.
The  four  major  players  in  the  MS  are  hyperinsulinemia,  hypertension, 
hyperlipidemia,  and hyperglycemia. Each member  of  this  deadly  quartet  has been 
demonstrated to be an independent risk factor for CHD and capable of working together 
in  a  synergistic  manner  to  accelerate  both  non-diabetic  atherosclerosis  and  the 
atheroscleropathy associated with MS, PD, and T2DM.
In  a  like  manner,  hyperuricemia,  hyperhomocysteinemia,  ROS,  and highly 
sensitive C- reactive protein (hsCRP)  each play an important role in expanding the 
original Syndrome X described by Reaven in the atherosclerotic process.  The above 
quartet  does  not  stand  alone  but  interacts  in  a  synergistic  manner  resulting  in  the 
progression  of  accelerated  atherosclerosis  and arterial  vessel  wall  remodelling  along 
with the original players.
In this study  serum uric acid levels in  diabetes  was examined. Uric acid as a 
marker  of  CAD  in  combination  with  other  risk  factors  which  includes  Metabolic 
Syndrome components was examined.
A control group consisting of non diabetics was also examined. Both the groups were 
age and sex matched. Uric acid levels and age were independent. 
Duration of the diabetes positively correlated with uric acid levels. Uric acid 
levels increase with increasing duration of diabetes and the association was statistically 
significant. Yoo et al. (2005) and Becker and Jolly (2006) reported that hyperglycemia 
was a remarkable risk factor for hyperuricemia. In a study of 3 681 Japanese adult, it 
was found that an elevation of serum uric acid concentration in males increased the risk 
of type 2 diabetes (Nakanishi et al.,  2003). It was concluded that hyperuricemia was 
positively associated with hyperglycemia.
In the present study males have higher uric acid level when compared to females. 
The  mean  uric  acid  levels  in  males  and  females  were  5.45±1.47  and  4.97±1.28 
respectively  although  then  difference  was  not  statistically  significant.  The  possible 
reason may be due to oestrogen promoting uric acid excretion (Sumino et al., 1999).     
In the present study serum uric acid correlated well with body mass index (BMI). 
The mean uric acid in subjects with BMI >25 was 6.40±1.006 and 4.23±0.73 in patients 
with  BMI<25.  The  difference  was  statistically  significant.  Waist  hip  ratio  is  an 
important measure of obesity especially central obesity. Waist circumference >102 cm 
in males and >88 cm in females is abnormal. In this present study the mean serum uric 
acid levels in patients  with  abnormal WHR and normal WHR were 5.91±1.31 and 
4.55±1.11 respectively and the difference was statistically significant.
Hyperuricemia has been associated with increasing body mass index (BMI) in 
recent studies and are even apparent in the adolescent youth [92-95].
Leptin levels are elevated and associated with insulin resistance in MS and early 
T2DM. Bedir A  et al.  have recently discussed the role of leptin as possibly being a 
regulator of SUA concentrations in humans and even suggested that leptin might be one 
of the possible candidates for the missing link between obesity and hyperuricemia (76).
In the present study uric acid levels were significantly elevated in patients with 
dyslipidemia.  The  mean  serum  uric  acid  level  in  patients  with  elevated  serum 
triglycerides was 6.37±1.02 and in patients with normal lipid profile was 4.60±1.14. The 
difference was statistically significant. Conen et al. (2004) and Schachter (2005) showed 
the same results. Hyperuricemia and hypertriglyceridemia are suggested to be associated 
with insulin resistance syndrome (Tai et al., 1999; Bo et al., 2001; Bosello and Zamboni, 
2000), and many investigators are studying the mechanisms of the emergence of this 
syndrome.  The  association  between  insulin  resistance  syndrome,  hyperuricemia,  and 
hypertriglyceridemia are complicated. This might be expected from the fact that uric 
acid  production  is  linked  to  glycolysis  and  that  glycolysis  is  controlled  by  insulin. 
Phosphoribosylpyrophosphate  (PPRP)  is  an  important  metabolite  in  this  respect.  Its 
availability depends on ribose-5-phosphate (R-5-P), the production of which is governed 
by glycolytic flux. Diversion of glycolytic intermediates toward R-5-P, PPRP, and uric 
acid will follow if there is diminished activity of GA3PDH (glyceraldehyde-3-phosphate 
dehydrogenase), which is regulated by insulin. Serum triglyceride concentrations may 
also increase, as might be expected from accumulation of glycerol-3-phosphate. Thus, 
intrinsic defects in GA3PDH and a loss of its  responsiveness to insulin,  by causing 
accumulation of glycolytic intermediates, may explain the association between insulin 
resistance, hyperuricemia, and hypertriglyceridemia (Leyva et al., 1998).
In the present study serum uric acids were significantly raised in patients with 
hypertension.  The  mean  uric  acid  levels  in  diabetics  with  hypertension  and  non 
hypertensive  were  6.6±1.105  and  4.79±1.18  respectively.  The  difference  was 
statistically significant. Lin KC et al. were able to demonstrate that blood pressure levels 
were predictive for cardiovascular disease incidence synergistically with serum uric acid 
level  [96].  Two separate  laboratories  have  demonstrated  the development  of  systemic 
hypertension  in  a  rat  model  of  hyperuricemia  developed  with  an  uricase  inhibitor 
(oxonic acid) after several weeks of treatment  [97,98]. This hypertension was associated 
with  increased  renin  and  a  decrease  in  neuronal  nitric  oxide  synthase  in  the 
juxtaglomerular  apparatus.  Prevention  of  this  hypertension  was  accomplished  by  an 
ACE inhibitor and to a lesser extent L-arginine. These findings indicate an interacting 
role of the renin- angiotensin system and the NOS enzyme. Hypertension, neural nitric 
oxide synthase (nNOS) and renin changes were also prevented by maintaining uric acid 
levels in the normal range with allopurinol or benziodarone (uricosuric). These above 
models  have  provided  the  first  challenging  evidence  that  uric  acid  may  have  a 
pathogenic role in the development of hypertension, vascular disease, and renal disease 
[99].
The total number of patients with ischemia and infarction in the study group were 
14, 4 respectively. The mean serum uric acid levels in these patients were 6.75±1.20 and 
7.3±0.96 respectively. Total number of hyperuricemic patients (serum uric acid>7 mg/dl 
in males, >6.5 mg/dl in females) were 5 in ischemic group and 2 in infarction group. 
Percentage of hyperuricemia is higher in patients with infarction than in patients with 
ischemia. In present study 78.57% of diabetic patients have serum uric acid >4 mg/dl, 
while only         23.3% of control group have serum uric acid >4 mg/dl (table 21). So 
serum uric acid >4 mg/dl should be considered as a Red Flag in those patients at risk for 
cardiovascular disease.
Table 21: Cases and controls in relation to uric acid.
    Serum uric acid          Cases           Controls
   No. Percentage      No. Percentage
          <4mg    15     21.43    23    76.7
          >4mg    55     78.57     7    23.3
P value: 0.0001 (significant)
An  epidemiological  link  between  elevated  serum  uric  acid  and an  increased 
cardiovascular risk has been recognized for many years.101,102 Observational studies show 
that serum uric acid concentrations are higher in patients with established coronary heart 
disease compared with healthy controls.103Elevated serum uric acid concentrations are 
also  found in  healthy  offspring of  parents  with coronary artery disease,  indicating a 
possible causal  relationship. However, hyperuricemia is also associated with possible 
confounding factors  including  elevated  serum  triglyceride  and  cholesterol 
concentrations,  blood  glucose,  fasting  and  post-carbohydrate plasma  insulin 
concentrations,  waist-hip  ratio  and  body  mass index.104,105About  one  quarter  of 
hypertensive  patients  have co-existent  hyperuricaemia106 and,  interestingly, 
asymptomatic hyperuricemia predicts future development of hypertension, irrespective 
of renal function.
Some studies have suggested that the importance of uric acid may be independent 
of confounding risk factors. Multivariate analysis of data from the MONICA cohort of 
1044  males  showed a  significant  association  between  raised  serum  uric  acid  and 
cardiovascular  mortality,  independent  of  body  mass  index,  serum cholesterol 
concentration,  hypertension,  diuretic  use,  alcohol intake  and  smoking  habits.99The 
Gothenburg prospective  study  of  1462  women  aged  38  to  60  years  also  found a 
significant relationship between serum uric acid concentration and total mortality during 
12-year  follow-up,  which  was  independent of  body  mass  index,  serum  lipid 
concentrations, smoking habit, blood pressure and age (100).
In contrast to these findings, several studies have suggested that the relationship 
between elevated serum uric acid and cardiovascular risk does not persist after correcting 
for other risk factors. The British Regional Heart Study of 7688 men aged 40 to 59 years 
showed a significant association between elevated serum uric acid and fatal and non-
fatal  coronary  disease  over  a  mean  16.8 years  (107).  However,  this  relationship 
disappeared  after  correcting for  other  risk  factors,  particularly  serum  cholesterol 
concentration. The Coronary Drug Project Research Group studied 2789 men, aged 30 to 
64  years,  and  found  that  the  association  between  increased cardiovascular  risk  and 
elevated serum uric acid concentration was not significant after consideration of other 
risk factors, and when thiazide diuretic use was considered (108).
In summary, although there is overwhelming evidence that elevated serum uric 
acid concentrations are strongly associated with increased cardiovascular risk and poor 
outcome, prospective population studies are often confounded by co-existent risk factors. 
In the present study serum uric acid positively correlated with duration of diabetes and 
cardiovascular  risk  factors  like  obesity  (high  BMI,  abnormal  waist  hip  ratio), 
hypertension, dyspidemia and the results were statistically significant. 
CONCLUSION
• Serum uric acid levels were significantly elevated in diabetic population.
• The serum uric acid level was independent of age and smoking status (in males).
• Mean serum uric acid levels were high in males.
• Significant positive correlation between serum uric acid levels and Body Mass 
Index as well as Waist Hip Ratio was noted.
• Elevated serum uric acid levels were significantly noted among those with
1. BMI>25, 
2. WHR abnormality, 
3. Dyslipidemia with high triglycerides, 
4. Hypertension.
• Serum uric acid levels increased with increasing duration of diabetes.
• Serum uric acid levels in diabetic patients with CAD were significantly higher. 
• Serum uric acid above 4 mg/dl in diabetic population is a marker or risk factor for 
CAD.  
RECOMMENDATIONS
• Multiple factors are associated with increased uric acid levels.
• Routine annual estimation of uric acid among diabetics from the identification of 
diabetes will help the clinician to find out the adequacy of 
i. Control of glycemic status. 
ii. Control of dyslidemia.
iii. Development of hypertension.
Diabetic patients with raised serum uric acid levels should be carefully monitored 
for CAD as well as other vascular episodes.
• A meticulous control of blood sugar, hypertension, body mass index, dyslidemia 
among diabetics bring down elevated uric acid level in diabetics.
SUMMARY
An  epidemiological  link  between  elevated  serum  uric  acid  and an  increased 
cardiovascular risk has been recognized for many years. Observational studies show that 
serum uric acid concentrations are higher in patients with established coronary heart 
disease compared with healthy controls. However, hyperuricemia is also associated with 
possible  confounding factors  including  elevated  serum  triglyceride  and  cholesterol 
concentrations,  blood  glucose,  fasting  and  post-carbohydrate plasma  insulin 
concentrations, waist-hip ratio and body mass index.
Diabetes mellitus is  strongly associated with hyperuricemia.  The present study 
was proposed to assess the uric acid status in patients with diabetes mellitus and to find 
its association with age, gender, BMI, WHR, smoking, dyslidemia, hypertension and 
CAD. 
With  rigid  criteria  patients  were  selected  carefully  and evaluated  after  getting 
institutional, ethical clearance and informed consent. 70 cases and 30 healthy age, sex 
matched individuals were kept as control. 
Serum uric acid levels were significantly higher in cases when compared to the 
control population. In the study group, BMI above 25 were seen in 47.14% of cases, 
while in control group only 13.33% had BMI >25. BMI>25 significantly correlated with 
hyperuricemia. Similarly abnormal high WHR positively correlated with hyperuricemia.
An  elevated  serum  uric  acid  level  was  noticed  among  those  who  had 
hypertension,  dyslipidemia,  coronary  artery  disease  and they  were  significant.  Mean 
serum uric acid in males was high compared to females. Smoking was not significantly 
associated with higher uric acid levels. Patients with longer duration of diabetes also had 
elevated uric acid levels.
Factors contributing to hyperuricemia in diabetes are:
• Hyperinsulinemia reduces urinary uric acid excretion and sodium excretion.
• Micro  vascular  disease  in  diabetes  mellitus  causes  local  tissue  ischemia  and 
decreased  renal  blood  flow.  Ischemia  increases  lactate  production  that  blocks 
urate secretion in proximal tubules. 
Meticulous  control  of  blood  sugar,  hypertension,  dyslipidemia,  body  weight  and 
abdominal girth form an essential component of diabetes which will bring down uric 
acid  levels.  It  is  worth  to  explore  uric  acid  levels  in  diabetic  patients  with  other 
cardiovascular  risk  factors  like  obesity,  dyspidemia,  hypertension  to  detect  early 
cardiovascular complications.
BIBLIOGRAPHY
1.  King  H,  Rewers  M.  Global  estimates  for  prevalence  of  diabetes  mellitus  and 
impaired  glucose  tolerance  in  adults.  WHO  Ad  Hoc  Diabetes  Reporting  Group. 
Diabetes Care 1993; 16:157–177.
2.  Fagot-Campagna  A,  Pettitt  DJ,  Engelgau  MM,  et  al.  Type  2  diabetes  among 
North  American children and adolescents:  an  epidemiologic  review and a  public 
health perspective. J Pediatr  2000; 136:664–672.
3.  Dabelea  D,  Pettitt  DJ,  Jones  KL,  et  al.  Type  2  diabetes  mellitus  in  minority 
children  and  adolescents.  An  emerging  problem.  Endocrinol  Metab  Clin  North 
Am  1999; 28:709–729.
4.  Dabelea  D,  Hanson  RL,  Bennett  PH,  et  al.  Increasing  prevalence  of  type  II 
diabetes in American Indian children. Diabetologia  1998; 41:904–910.
5.  Kaufman FR. Type 2 diabetes mellitus in children and youth:  a new epidemic. 
J Pediatr Endocrinol Metab 2002;15[Suppl 2]:737–744.
6. Expert  Committee  on the  Diagnosis  and  Classification of  Diabetes  Mellitus:  Follow-up 
report on the diagnosis of diabetesmellitus. Diabetes Care 26:3160–3167, 2003.
7.  Gavin  JR  III,  Alberti  KGMM,  Davidson  MB,  et  al.  Report  of  the  Expert 
Committee  on  the  Diagnosis  and  Classification  of  Diabetes  Mellitus.  Diabetes 
Care 1997;20:1183–1197.
8.WHO Consultation  Group.  Definition,  diagnosis  and classification  of  diabetes  
mellitus  and  its  complications ,  2nd  ed.  Part  1:  Diagnosis  and  classification  of 
diabetes  mellitus  WHO/NCD/NCS/99.  Geneva:  World  Health  Organisation, 
1999:1–59.
9.Edelstein  SL,  Knowler  WC,  Bain  RP,  et  al.  Predictors  of  progression  from 
impaired  glucose  tolerance  to  NIDDM:  an  analysis  of  six  prospective  studies. 
Diabetes 1997;46:701–710.
10.  The  DECODE  study  group.  Glucose  tolerance  and  mortality:  comparison  of 
WHO and American Diabetes Association diagnostic  criteria.  European Diabetes 
Epidemiology  Group.  Diabetes  epidemiology:  collaborative  analysis  of 
diagnostic criteria in Europe. Lancet  1999; 354:617–621.
11.  Gabir  MM,  Hanson  RL,  Dabelea  D,  et  al.  Plasma  glucose  and  prediction  of 
microvascular  disease  and  mortality:  evaluation  of  1997  American  Diabetes 
Association  and  1999  World  Health  Organization  criteria  for  diagnosis  of 
diabetes. Diabetes Care 2000; 23:1113–1118
12.  Genuth S,  Alberti  KG, Bennett  P,  et  al.  Follow-up report  on the diagnosis  of 
diabetes mellitus. Diabetes Care  2003; 26:3160–3167
13.  Pincus  G,  White  P.  On  the  inheritance  of  diabetes  mellitus.  II.  Further 
analysis of family histories. Am J Med Sci  1034; 188:159–169.
14.  Harris  H.  The  familial  distribution  of  diabetes:  a  study  of  the  relatives  of 
1241 diabetic propositi. Ann Eugenet  1950;15:95–119.
15.  Gottlieb  MS.  Diabetes  in  offsprings  and  siblings  of  juvenile-  and  maturity-
onset type diabetics. J Chronic Dis 1980;33:331–339.
16.  Newman B, Selby JV, King M-C, et  al.  Concordance for type 2 (non-insulin-
dependent) diabetes mellitus in male twins. Diabetologia  1987;30:763–768.
17.  Medici  F,  Hawa  M,  Ianari  A,  et  al.  Concordance  rate  for  type  2  diabetes 
mellitus  in  monozygotic  twins:  actuarial  analysis.  Diabetologia  1999;42:146–
150.
18.  Poulsen  P,  Kyvik  KO,  Vaag  A,  et  al.  Heritability  of  type  2  (non-insulin 
dependent)  diabetes  mellitus  and  abnormal  glucose  tolerance—a  population-
based twin study. Diabetologia  1999;42:125–127.
19.Rich  SS.  Mapping  genes  in  diabetes:  genetic  epidemiological  perspective. 
Diabetes 1990;39:1315–1319.
20.  Cook  JT,  Shields  DC,  Page  RC,  et  al.  Segregation  analysis  of  NIDDM  in 
Caucasian families. Diabetologia  1994;37:1231–1240.
21.  Perley  MJ,  Kipnis  DM.  Plasma  insulin  responses  to  oral  and  intravenous 
glucose:  studies  in  normal  and  diabetic  subjects.  J  Clin  Invest 1967;46:1954–
1962.
22.  Cerasi  E,  Luft  R.  The plasma insulin response to glucose infusion in healthy 
subjects and in diabetes mellitus. Acta Endocrinol (Copenh)  1967;55:278–304.
23.  Brunzell  JD,  Robertson  RP,  Lerner  RL,  et  al.  Relationships  between  fasting 
plasma glucose levels  and insulin secretion during intravenous glucose tolerance 
tests. J Clin Endocrinol Metab 1976;42:222–229.
24.Lillioja  S,  Mott  DM,  Howard  B,  et  al.  Impaired  glucose  tolerance  as  a 
disorder  of  insulin  action:  longitudinal  and  cross-sectional  studies  in  Pima 
Indians. N Engl J Med  1988;318:1217–1225.
25.Warram JH,  Martin  BC,  Krolewski  AS,  et  al.  Slow glucose  removal  rate  and 
hyperinsulinemia precede the development of type II  diabetes in the offspring of 
diabetic parents. Ann Intern Med 1990;113:909–915.
26.  Global Burden of Disease Estimate of 176,525,312 Individuals with Diabetes 
Mellitus  in  2000.  Data  generated by World  Health  Organization and available  at 
http://www.who.int/ncd/dia/ databases4.htm
27.  Warram JH,  Martin  BC,  Krolewski  AS,  et  al.  Slow glucose  removal  rate  and 
hyperinsulinemia precede the development of type II  diabetes in the offspring of 
diabetic patients. Ann Intern Med  1990;113:909–915.
28.Lillioja  S,  Mott  DM,  Howard  BV,  et  al.  Impaired  glucose  tolerance  as  a 
disorder  of  insulin  action.  Longitudinal  and  cross-sectional  studies  in  Pima 
Indians. N Engl J Med  1988;318:1217–1225.
29. IDF Diabetes Atlas 4 t h  Edition, 2009.
30. WHO (2003), Tech, Rep.Ser., N 916.
31.  Alwin  C.  Powers.  Diabetes  mellitus.  Harrison’s  principles  of  Internal 
Medicine 17 t h  Edition, 2008, 2275-2304.
32.   Alwin  C.  Powers.  Diabetes  mellitus.Harrison’s  principles  of  Internal 
Medicine 17 t h  Edition,2008, 2275-2304.
33.  Robert  H.Eckel,  Harrison’s  internal  medicine  17 t h edition,  chap  236, 
1509-1514.
34.  Thompson  D,  Wolf  AM.  The  medical-care  cost  burden  of  obesity.  Obes  Rev 
2001;2:189–197.
35.  Vanitallie  TB.  Body  weight,  morbidity,  and  longevity.  In:  Bjorntorp  P, 
Brodoff BN, eds. Obesity. Philadelphia: JB Lippincott Co, 1992.
36. Montague CT, O'Rahilly S. The perils of portliness: causes and consequences 
of visceral adiposity. Diabetes  2000;49:883–888.
37.  Vanitallie  TB.  Body  weight,  morbidity,  and  longevity.  In:  Bjorntorp  P, 
Brodoff BN, eds. Obesity. Philadelphia: JB Lippincott Co, 1992.
38.  Hubert  HB, Feinleib M, McNamara PM, et al.  Obesity as an independent risk 
factor  for  cardiovascular  disease:  a  26-year  follow-up  of  participants  in  the 
Framingham Heart Study. Circulation  1983;67:968–977.
39.  Billington  CJ,  Brigg  JE,  Grace  M,  et  al.  Effects  of  intracerebroventricular 
injection  of  neuropeptide  Y  on  energy  metabolism.  Am  J  Physiol  1991;260: 
R321–R327.
40.  Cowley  MA,  Smith  RG,  Diano  S,  et  al.  The  distribution  and  mechanism  of 
action  of  ghrelin  in  the  CNS  demonstrates  a  novel  hypothalamic  circuit 
regulating energy homeostasis. Neuron  2003;37:649–661.
41. Grundy SM. Mechanism of cholesterol gallstones formation.  Semin Liver Dis 
1983;3:97–111.
42.  Calle  EE,  Rodriguez C,  Walker-Thurmond K,  et  al.  Overweight,  obesity  and 
mortality  from  cancer  in  a  prospectively  studied  cohort  of  US  adults.  N  Engl  J 
Med  2003;348:1625–1635.
43.Roch-Ramel F, Werner D, Guisan B. Urate transport in brush-border membrane of human 
kidney. Am J Physiol Renal Physiol 1994;266:F797.
44.Roch-Ramel F, Guisan B, Diezi J. Effects of uricosuric and antiuricosuric agents on urate 
transport in human brush-border membrane vesicles. J Pharm Exp Ther 1997;280:839.
45.  Lipkowitz  MS, Leal-Pinto E,  Rappoport  JZ,  et  al.  Functional  reconstitution,  membrane 
targeting, genomic structure and chromosomal localization of a human urate transporter. J Clin 
Invest 2001;107:1103.
46. van Aubel RA, Smeets PH, Peters JG, et al.  The MRP4/ABCC4 gene encodes a novel 
apical organic anion transporter in human kidney proximal tubules: Putative efflux pump for 
urinary cAMP and cGMP. J Am Soc Nephrol 2002;13:595.
47. Johnson RJ, Srinivas T, Cade JR, et al. Uric acid, evolution and primitive cultures. Semin 
Nephrol 2005;25:3.
48. Kanabrocki EL, Third JL, Ryan MD, et al. Circadian relationship of serum uric acid and 
nitric oxide. JAMA 2000;283:2240.
49. Duk Hee Kong, Richard J Johnson, Diseases of Kidney & Urinary tract, 8th edition, chapter 
76, 1987-1988.
50. Culleton BF, Larson MG, Kannel WB, et al. Serum uric acid and risk of cardiovascular 
disease and mortality: the Framingham Heart Study. Ann Intern Med 1999;31:7.
51. Johnson RJ, Feig DI, Kang DH, et al. Resurrection of uric acid as a causal risk factor for 
essential hypertension. Hypertension 2005;45:18.
52. SÃndstrom J, Sullivan L, D'Agostino RB, et al. Relations of serum uric acid to longitudinal 
blood pressure tracking and hypertension incidence. Hypertension 2005;45:28.
53. Nakagawa T, Hu H, Zharikov S,  et  al.  A casual  role for uric  acid in fructose-induced 
metabolic syndrome. Am J Physiol Renal Physiol 2006;290:F625.
54. Masuo K, Kawaguchi H, Mikami H, et al.  Serum uric acid and plasma norepinephrine 
concentrations  predict  subsequent  weight  gain  and  blood  pressure  elevation.  Hypertension 
2003;42:474.
55. Nakanishi N, Okamato M, Yoshida H, et al. Serum uric acid and risk for development of 
hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. 
Eur J Epidemiol 2003;18:523.
56.  Facchini F, Chen YD, Hollenbeck CB, et al. Relationship between resistance to insulin-
mediated  glucose  uptake,  urinary  uric  acid  clearance,  and  plasma  uric  acid  concentration. 
JAMA 1991;266:3008.
57. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat 
by a novel crystal-independent mechanism. Hypertension 2001;38:1101.
58. Nakagawa T, Mazzali M, Kang DH, et al. Hyperuricemia causes glomerular hypertrophy in 
the rat. Am J Nephrol 2003;23:2.
59. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary arteriolopathy in rats 
by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002;282:F991.
60.  Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. 
Kidney Int 2005;67:1739.
61. Watanabe S, Kang DH, Feng L, et al. Uric acid, hominoid evolution and the pathogenesis 
salt-sensitivity. Hypertension 2002;40:355.
62.  Kanellis  J,  Watanabe  S,  Li  JH,  et  al.  Uric  acid  stimulates  monocyte  chemoattractant 
protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and 
cyclooxygenase-2. Hypertension 2003;41:1287.
63. Kang DH, Yu ES, Park JE, et al. Uric acid induced C-reactive protein (CRP) expression via 
upregulation of angiotensin type 1 receptors (AT1) in vascular endothelial cells and smooth 
muscle cells (abstract). J Am Soc Nephrol 2003;14:136A.
64.  Feig DI,  Johnson RJ.  Hyperuricemia in  childhood primary hypertension.  Hypertension. 
2003;42:247–52.
65. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary 
and renal hypertension. N Engl J Med. 1966;275:457–64.
66.  Bulpitt CJ. Serum uric acid in hypertensive patients. Br Heart J. 1975;37:1210–5.
67. Cuspidi C, Valerio C, Sala C, et al. Lack of association between serum uric acid and organ 
damage  in  a  never-treated  essential  hypertensive  population  at  low  prevalence  of 
hyperuricemia. Am J Hypertens. 2007;20:678–85. 
68. Brand FN, McGee DL, Kannel WB, Stokes J, III, Castelli WP. Hyperuricemia as a risk 
factor of coronary heart disease: the Framingham Study. Am J Epidemiol. 1985;121:11–8. 
69. Kinsey D, Walther R, Sise HS,White-law G, Smithwick R. Incidence of hyperuricemia in 
400 hypertensive patients.Circulation.1961;24:972-3.
70. Hayden  MR,  Tyagi  SC.  Intimal  redox  stress:  Accelerated  atherosclerosis  in  metabolic 
syndrome and type 2 diabetes mellitus. Atheroscleropathy. Cardiovasc Diabetol. 2002;1:3. doi: 
10.1186/1475-2840-1-3.
71.  Williamson JR, Kilo C, Ido Y. The role of cytosolic reductive stress in oxidant formation 
and  diabetic  complications.  Diabetes  Res  Clin  Pract.  1999;45:81–82.  doi: 
10.1016/S0168-8227(99)00034-0. 
72.   Aronson  D,  Rayfield  EJ.  How  hyperglycemia  promotes  atherosclerosis:  molecular 
mechanisms. Cardiovasc Diabetol. 2002;1:1. doi: 10.1186/1475-2840-1-1. 
73. Santos CX, Anjos EI, Augusto O. Uric acid oxidation by peroxynitrite: multiple reactions, 
free  radical  formation,  and  amplification  of  lipid  oxidation.  Arch  Biochem  Biophys. 
1999;372:285–294. doi: 10.1006/abbi.1999.1491. 
74.  Abuja  PM.  Ascorbate  prevents  prooxidant  effects  of  urate  in  oxidation  of  human low 
density lipoprotein. FEBS Lett. 1999;446:305–308. doi: 10.1016/S0014-5793(99)00231-8. 
75.  Griendling  KK,  Sorescu  D,  Ushio-Fukai  M.  NAD(P)H oxidase:  role  in  cardiovascular 
biology and disease. Circ Res. 2000;86:494–501.
76. Bedir A, Topbas M, Tanyeri F, Alvur M, Arik N. Leptin might be a regulator of serum uric 
acid concentrations in humans. Jpn Heart J. 2003;44:527–536. doi: 10.1536/jhj.44.527.
77.  Conen  D,  Wietlisbach  V,  Bovet  P,  Shamlaye  C,  Riesen  W,  Paccaud  F,  Burnier  M. 
Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in 
a developing country. BMC Public Health. 2004;4:9. doi: 10.1186/1471-2458-4-9.
78. Bonora E, Targher G, Zenere MB, Saggiani F, Cacciatoryi V, Tosi F, Travia D, Zenti MG, 
Branzi P, Santi L, Muggeo M. Relationship of uric acid concentration to cardiovascular risk 
factors in young men. The role of obesity and central fat distribution, The Verona Young Men 
Atherosclerosis Risk Factors Study. Int J Obes Relat Metab Disord. 1996;20:975–980.
79. Fang J,  Alderman MH.  Serum uric  acid  and  cardiovascular  mortality  the  NHANES I 
epidemiologic  follow-up  study,  1971–1992.  National  Health  and  Nutrition  Examination 
Survey. JAMA. 2000;283:2404–2410. doi: 10.1001/jama.283.18.2404. 
80.  Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Lakka TA, Salonen 
JT. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged 
men:  a  prospective  cohort  study.  Arch  Intern  Med.  2004;164:1546–1551.  doi: 
10.1001/archinte.164.14.1546.
81.  Nyyssonen K, Porkkala-Sarataho E, Kaikkonen J, Salonen JT. Ascorbate and urate are the 
strongest determinants of plasma antioxidative capacity and serum lipid resistance to oxidation 
in Finnish men. Atherosclerosis. 1997;130:223–233. doi: 10.1016/S0021-9150(96)06064-9.  
82.  Naghavi M, John R, Naguib S, Siadaty MS, Grasu R, Kurian KC, van Winkle WB, Soller 
B, Litovsky S, Madjid M, Willerson JT, Casscells W. pH Heterogeneity of human and rabbit 
atherosclerotic  plaques;  a  new insight  into  detection  of  vulnerable  plaque.  Atherosclerosis. 
2002;164:27–35. doi: 10.1016/S0021-9150(02)00018-7.
83. Hayden MR, Tyagi SC. Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) 
with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc 
Diabetol. 2003;2:2. doi: 10.1186/1475-2840-2-2.
84.  Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad 
D, Lan HY, Feng L,  Johnson RJ.  Uric acid stimulates monocyte chemoattractant protein-1 
production  in  vascular  smooth  muscle  cells  via  mitogen-activated  protein  kinase  and 
cyclooxygenase-2.  Hypertension.  2003;41:1287–1293.  doi: 
10.1161/01.HYP.0000072820.07472.3B. 
85.  Olexa P, Olexova M, Gonsorcik J, Tkac I, Kisel'ova J, Olejnikova M. Uric acid – a marker 
for  systemic  inflammatory  response  in  patients  with  congestive  heart  failure?  Wien  Klin 
Wochenschr. 2002;114:211–215.
86.  Schlotte V, Sevanian A, Hochstein P, Weithmann KU. Effect of uric acid and chemical 
analogues on oxidation of human low density lipoprotein in vitro. Free Rad Biol Med1998; 
25:839–47.
87.  Abuja  PM.  Ascorbate  prevents  prooxidant  effects  of  urate  in  oxidation  of  human low 
density lipoprotein. FEBS Lett1999; 446:305–8.
88. Boogaerts MA, Hammerschmidt DE, Roelant C, Verwilghen RL, Jacob HS. Mechanisms 
of vascular damage in gout and oxalosis: crystal induced, granulocyte mediated, endothelial 
injury. Thromb Haemost1983; 50:576–80.
89. Falasca GF, Ramachandrula A, Kelley KA, O'Connor CR, Reginato AJ. Superoxide anion 
production and phagocytosis of crystals by cultured endothelial cells. Arthritis Rheum1993; 
36:105–16. 
90. Duff GW, Atkins E, Malawista SE. The fever of gout: urate crystals activate endogenous 
pyrogen  production  from  human  and  rabbit  mononuclear  phagocytes.  Trans  Assoc  Am 
Physicians1983; 96:234–45.
91. Patetsios P, Rodino W, Wisselink W, Bryan D, Kirwin JD, Panetta TF. Identification of 
uric acid in aortic aneurysms and atherosclerotic artery. Ann N Y Acad Sci1996; 800:243–5.
92.  Conen  D,  Wietlisbach  V,  Bovet  P,  Shamlaye  C,  Riesen  W,  Paccaud  F,  Burnier  M. 
Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in 
a developing country. BMC Public Health. 2004;4:9. doi: 10.1186/1471-2458-4-9. 
93.  Ogura T, Matsuura K, Matsumoto Y, Mimura Y, Kishida M, Otsuka F, Tobe K. Recent 
trends  of  hyperuricemia  and  obesity  in  Japanese  male  adolescents,  1991  through  2002. 
Metabolism. 2004;53:448–453. doi: 10.1016/j.metabol.2003.11.017.  
94.   Pan WH, Flegal  KM, Chang HY, Yeh WT, Yeh CJ, Lee WC. Body mass index and 
obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for 
definitions of overweight and obesity for Asians. Am J Clin Nutr. 2004;79:31–39. 
95. Bonora E, Targher G, Zenere MB, Saggiani F, Cacciatoryi V, Tosi F, Travia D, Zenti MG, 
Branzi P, Santi L, Muggeo M. Relationship of uric acid concentration to cardiovascular risk 
factors in young men. The role of obesity and central fat distribution, The Verona Young Men 
Atherosclerosis Risk Factors Study. Int J Obes Relat Metab Disord. 1996;20:975–980.
96.  Lin KC, Tsao HM, Chen CH, Chou P. Hypertension was the major risk factor leading to 
development  of  cardiovascular  diseases  among  men  with  hyperuricemia.  J  Rheumatol. 
2004;31:1152–1158. 
97.  Wu X,  Wakamiya M,  Vaishnav S,  Geske  R,  Montgomery  C,  Jr,  Jones  P,  Bradley  A, 
Caskey CT. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice.  Proc Natl 
Acad Sci U S A. 1994;91:742–746.  
98. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, 
Johnson  RJ.  Elevated  uric  acid  increases  blood  pressure  in  the  rat  by  a  novel  crystal-
independent mechanism. Hypertension. 2001;38:1101–1106.
99.  Liese AD, Hense HW, Lowel H, Doring A, Tietze M, Keil U. Association of serum uric 
acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in 
the  MONICA  Augsburg  cohort.  World  Health  Organization  Monitoring  Trends  and 
Determinants in Cardiovascular Diseases. Epidemiology1999; 10:391–7. 
100.  Bengtsson  C,  Lapidus  L,  Stendahl  C,  Waldenstrom  J.  Hyperuricaemia  and  risk  of 
cardiovascular disease and overall death. A 12-year follow-up of participants in the population 
study of women in Gothenburg, Sweden. Acta Med Scand1988; 224:549–55.
101.Kohn  PM,  Prozan  GB.  Hyperuricemia:  relationship  to  hypercholesterolemia  and  acute 
myocardial infarction. JAMA1959; 170:1909–15. 
102. Beard JT. Serum uric acid and coronary heart disease. Am Heart J1983; 106:397–400. 
103.  Torun  M,  Yardim S,  Simsek  B,  Burgaz  S.  Serum uric  acid  levels  in  cardiovascular 
diseases. J Clin Pharm Ther1998; 23:25–9.
104. Lee J, Sparrow D, Vokonas PS, Landsberg L, Weiss ST. Uric acid and coronary heart 
disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. The 
Normative Aging Study. Am J Epidemiol1995; 142:288–94.
105. Patten RL, Hewitt D, Waldman GT, Jones G, Little JA. Associations of plasma high-
density lipoprotein cholesterol with clinical chemistry data. Circulation1980;
106.  Tykarski  A.  Evaluation  of  renal  handling  of  uric  acid  in  essential  hypertension: 
hyperuricemia related to decreased urate secretion. Nephron1991; 59:364–8.
107. Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary 
heart disease events. Heart1997; 78:147–53.
108. The Coronary Drug Project Research Group. Serum uric acid: its association with other 
risk factors and with mortality in coronary heart disease. J Chron Dis, 1976; 29:557–69.
109. Diseases of the Kidney & Urinary Tract, 8th Edition, Schrier, Robert W; 76:1986.
Serum uric acid levels in type 2 Diabetes Mellitus and               its 
association with cardiovascular risk factors.
Name:
Age:                                                                               Sex: M/F
IP /OP no:                                                                      Ward:
Duration of diabetes:
Symptoms:
Polyuria:
Polydipsia:
Polyphagia:
Chest pain/ swelling of extremities/ breathlessness:
Headache:
Vomiting:
Fever:
Numbness/ Paraesthesia:
Blurring of vision:
Decreased urine output:
Personal history:
Smoking:
Alcohol:
Drug abuse:
Dietary habit:
Family history of diabetes:
Clinical examination:
Pulse:
Blood pressure:
Respiratory rate:
Temperature:
Body mass index:
Waist hip ratio:
Pallor:
Cyanosis/ icterus/ clubbing:
Pedal oedema:
Skin lesions: acanthosis nigricans/ markers of dyslipidemia
Cardiovascular system: 
Respiratory system:
Abdomen:
Central and peripheral nervous system:
Evidence of peripheral vascular disease:
Opthal examination including Fundus:
Investigations:
Blood sugar (f):
Blood sugar (pp):
Blood urea:
Serum creatinine:
Serum uric acid:
Urine albumin:
Urine sugar:
Urine deposits:
Total cholesterol:
LDL:
HDL:
VLDL:
risk factor:
Chest X-ray:
ECG:
Echocardiogram:
USG abdomen:
